NRG
CRL icon

Nemes Rush Group’s Charles River Laboratories CRL Stock Holding History

Nemes Rush Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13K Hold
5
– – ﹤0.01% 852
2026
Q1 		$863 Buy
+5
New +$927 ﹤0.01% 842
2025
Q4 		– Sell
-2
Closed -$313 – 994
2025
Q3 		$313 Hold
2
– – ﹤0.01% 665
2025
Q2 		$303 Hold
2
– – ﹤0.01% 701
2025
Q1 		$301 Hold
2
– – ﹤0.01% 689
2024
Q4 		$369 Buy
+2
New +$385 ﹤0.01% 707

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Nemes Rush Group's CRL Position: Q2 2026 in Review

Nemes Rush Group held its Charles River Laboratories (CRL) position steady in Q2 2026 at 5 shares worth $1.13K. The position accounts for ﹤0.01% of the portfolio, ranked #852.

Nemes Rush Group first reported a position in CRL in Q4 2024 and has held it in 6 quarters since. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Nemes Rush Group held 5 shares of Charles River Laboratories worth $1.13K as of Q2 2026.
  • Nemes Rush Group left its Charles River Laboratories share count unchanged in Q2 2026.
  • Charles River Laboratories made up ﹤0.01% of Nemes Rush Group's portfolio in Q2 2026, its #852 holding.
  • Nemes Rush Group first reported a position in Charles River Laboratories in Q4 2024 and has held it in 6 quarters since.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.